Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > January 21, 2026
Daily News
January 21, 2026
- MHLW Official Making Rounds to Rally Private Support for Drug Discovery Fund
January 21, 2026
- Shionogi to Lift Stake in ViiV to 21.7% as Pfizer Exits
January 21, 2026
- Kobe, iPark Institute, Partners Sign Pact to Accelerate Innovation at KBIC
January 21, 2026
- Cabinet OKs Subsidy to Boost Antibiotic API Stockpiles, Allocates 7.1 Billion Yen from Reserve
January 21, 2026
- Fuji Pharma Earns Approval for High-Dose Stelara Biosimilar
January 21, 2026
- PMDA Chief Vows Stronger Support for Drug Discovery, Orphan Designations
January 21, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…